Morco (Fluticasone Furoate)

Fluticasone furoate binds to glucocorticoid receptors in the nasal mucosa, suppressing the production of inflammatory cytokines and decreasing vascular permeability. This action reduces swelling and irritation of the nasal passages, leading to symptom improvement.

The dosage of Morco is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms and clinical response. Patients should follow the prescriber’s instructions and the product label for proper use.

Safety data for fluticasone furoate in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Morco.

To order Morco, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Morco’s active ingredient, fluticasone furoate, has a high receptor affinity and a long residence time, allowing once‑daily dosing for many patients. Compared with alternatives such as mometasone furoate or budesonide, it may offer comparable efficacy with a convenient dosing schedule, though individual response can vary.

Morco should be stored at room temperature, below 25 °C. Keep the spray in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use.

Morco is administered as a nasal spray. The patient gently shakes the bottle, inserts the tip into one nostril, and sprays the prescribed number of sprays while inhaling gently. The same procedure is repeated in the other nostril if directed by the prescriber.

Serious risks, though rare, include nasal septal perforation, severe allergic reactions such as anaphylaxis, adrenal suppression with prolonged high‑dose use, and opportunistic fungal infections of the nasal cavity. Patients should seek immediate medical attention if they experience unusual bleeding, vision changes or signs of systemic infection.

Morco should be avoided in individuals with known hypersensitivity to fluticasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated nasal infections, recent nasal surgery, or those for whom systemic corticosteroid exposure is contraindicated.